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a b s t r a c t
Aims: An epidemiological survey of diabetic foot infections (DFIs) in Lisbon, stratifying the
bacterial profile based on patient demographical data, diabetic foot characteristics (PEDIS
classification), ulcer duration and antibiotic therapy.
Methods: A transversal observational multicenter study, with clinical data collection using a
structured questionnaire and microbiological products (aspirates, biopsies or swabs col-
lected using the Levine method) of clinically infected foot ulcers of patients with diabetes
mellitus (DM).
Results: Forty-nine hospitalized and ambulatory patients were enrolled in this study, and
147 microbial isolates were cultured. Staphylococcus was the main genus identified, and
methicillin-resistant Staphylococcus aureus (MRSA) was present in 24.5% of total cases. In the
clinical samples collected from patients undergoing antibiotic therapy, 93% of the antibiotic
regimens were considered inadequate based on the antibiotic susceptibility test results. The
average duration of an ulcer with any isolated multi-drug resistant (MDR) organism was 29
days, and previous treatment with fluoroquinolones was statistically associated with multi-
drug resistance.
Conclusions: Staphylococcus aureus was the most common cause of DFIs in our area. Preva-
lence and precocity of MDR organisms, namely MRSA, were high and were probably related
to previous indiscriminate antibiotic use. Clinicians should avoid fluoroquinolones and
more frequently consider the use of empirical anti-MRSA therapy.
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* Corresponding author. Tel.: +351 934 855 822; fax: +351 213 560 368.
E-mail address: joaojoaomendes@hotmail.com (J.J. Mendes).
Abbreviations: CRTB, clinically relevant tissue burden; DFI, diabetic foot infection; DFU, diabetic foot ulcer; DM, diabetes mellitus; ESBL,
extended-spectrum b-lactamase; HCP, health care provider; MDR, multi-drug resistant; MRSA, methicillin-resistant Staphylococcus aureus;
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Diabetes mellitus (DM) is a serious health problem that is
rapidly expanding worldwide [1]. One of the more frequent
diabetic complications is diabetic foot, which results from a
complex interaction between a number of risk factors.
Neuropathy (with alterations in motor, sensitive and auto-
nomic functions) has a central role, causing ulcerations
because of trauma or excessive pressure on deformed feet
that lack protective sensitivity [2]. Once the protective layer of
skin is broken, the deep tissues are exposed to bacterial
colonization. Infections are facilitated by immunological
deficits (especially in neutrophils), which are related to DM,
and they rapidly progress to the deep tissues. Patients with DM
frequently require minor or major amputations of the lower
limbs (15–27%), and in more than 50% of cases, infection is the
preponderant factor [2].
Staphylococcus aureus is the most prevalent isolate in
diabetic foot ulcers (DFUs), together with other aerobes
(including Staphylococcus epidermidis, Streptococcus spp., Pseudo-
monas aeruginosa, Enterococcus spp. and coliform bacteria) and
anaerobes [3,4]. Because of the polymicrobial nature of
diabetic foot infections (DFIs), Karchmer and Gibbons [5]
questioned the need for precisely defining the causative
microorganism and suggested a treatment strategy based only
on the knowledge of the general epidemiology. More recently,
an increase in the incidence of multi-drug resistant (MDR)
organisms, namely methicillin-resistant S. aureus (MRSA) and
extended-spectrum b-lactamase (ESBL)-producing gram-neg-
ative bacteria, is threatening the outcome of anti-infectious
therapy in the community and in hospitalized patients [4].
Therefore, the current guidelines [6] and expert opinion [7]
advise providers to obtain specimens for culture before
initiating empiric antibiotic therapy to help with the selection
of a definitive therapy.
Although Portugal has one of the highest prevalences of
DM, lower extremity amputations [8] and MRSA skin and soft
tissue infections [9] in Europe, there is virtually no data on the
prevalence and characterization of DFIs. Therefore, we
performed an epidemiological survey of DFIs in Lisbon,
stratifying the bacterial profiles based on patient demograph-
ical data, characteristics of diabetic foot (PEDIS classification),
ulcer duration and current and recent (3 months prior)
antibiotic therapy.
2. Subjects, materials and methods
This transversal observational study was conducted at 4
clinical centers (2 outpatient clinics, 1 general surgery ward
and 1 vascular surgery ward) in Lisbon from January 2010 to
June 2010. A structured questionnaire was developed to record
medical histories, examination details and investigation
reports by health care providers (HCPs). Specimens were
collected from patients with DM and clinically infected foot
ulcers, as advised by current clinical guidelines [6]. A DFU was
defined as a full-thickness wound below the ankle in a diabetic
patient, irrespective of duration [10]. Infection was defined
clinically by symptoms and signs of inflammation, asdescribed by the infection item on the PEDIS system [10].
Specimens were obtained from patients before the first dose of
antibiotics or while under antibiotic therapy with progression
of infection signs and clinical deterioration of the ulcer.
This study was approved by the Faculty of Medicine of the
University of Lisbon Research Ethics Committee and the
Portuguese Data Protection Authority, and written informed
consent was obtained for every patient.
2.1. Clinical characterization
For clinical characterization, 9 study factors were recorded for
each patient: age, gender, DM duration (from diagnosis), last
HbA1c value (accepted if collected in the last 3 months),
hypertension and dyslipidemia (as defined according to the
American Diabetes Association (ADA) guidelines for the
diabetic population [11]), active tobacco abuse (defined as
20 packs in the previous year), presence of ischemic heart
disease (defined as previous history of myocardial infarction,
coronary artery bypass graft or percutaneous transluminal
coronary angioplasty) and chronic renal failure (defined as
calculated glomerular filtration rate < 30 mL min1 1.73 m2,
permanent renal replacement therapy or previous transplant).
2.2. Diabetic foot characterizations
For characterization of diabetic foot, we used the International
Working Group of the Diabetic Foot PEDIS system [10], which
classified all foot ulcers in subcategories of five main
categories (perfusion, extent/size, depth/tissue loss, infection
and sensation), according to strict criteria. For the definition of
osteomyelitis, a minimum of a positive probe-to-bone test [12]
was accepted, but clinicians were encouraged to substantiate
their diagnosis with the appropriate imaging studies. The
number of previous ulcers and previous minor (toe or part of
the foot) or major (above the ankle) amputations was also
recorded.
2.3. Antibiotic therapy
HCPs were asked to register all current and recent (over the
previous 3 months) antibiotic therapies.
2.4. Collection of samples
All HCPs were instructed on the proper methods for the
collection of culture material, and a written protocol was
provided. In the case of abscess with intact integument (and
other closed lesions), the protocol suggested sampling by
needle aspiration under strict aseptic technique. For ulcers
and other open wounds, biopsy specimens were required,
except in situations where the HCP considered that the
invasive procedure could place the patient at risk (pain
induction or risk of enlarging the ulcer). In only these
situations, superficial swab samples were accepted, in strict
accordance with the National Institute for Health and Clinical
Excellence diabetic foot guideline [6]. For either of the
procedures, debridement of necrotic tissue and cleansing
with simple saline before sampling was obligatory. For
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scribed [13], were required. For swab sampling, HCPs were
instructed on a standardized procedure [14], based on the
Levine 1 cm2 swab method, using a flocked swab (ESwab
Collection System, Copan).
2.5. Transport
Aspirates were transported in buffered isotonic agar with
reduction agent media (Port-A-Cul Vial, BD BBL), and biopsies
and swabs were transported in modified liquid Amies medium
(ESwab Preservation System, Copan). Transport to the labora-
tory (Microbiology Laboratory, Faculty of Veterinary Medicine,
Technical University of Lisbon) within 2 h of collection was
assured by an on-call express courier.
2.6. Processing and microbiological analysis of wound
specimens
Standard methods for sample processing and isolation and
identification of aerobic and anaerobic bacteria were used [15].
Biopsy samples were weighed to the nearest milligram in
sterile Petri dishes and homogenized in PBS using a pearl jar. A
100-mL volume of the homogenate was used for serial dilutions
in PBS. For aspirate samples, a 100-mL volume of the recovered
fluid was directly used for serial dilutions in PBS. Swab
samples were vortexed with the swab inside for 5 s, and then a
100-mL volume of the suspension was used for serial dilutions
in PBS. Quantification was performed using the 10-fold serial
dilution method [15], and 100 mL of each dilution was
inoculated onto MacConkey agar (Merck)/Columbia ANC agar
with 5% sheep blood (BioMe´rieux) and, in duplicate, in
Schaedler agar with 5% sheep blood (BioMe´rieux). The first
two plates were incubated under aerobic conditions at 35 8C
for 24–48 h, and the two Schaedler plates were incubated
under anaerobic conditions (Anaerocult A, Merck) for 48–96 h.
Additionally, samples were inoculated in Brain Heart Infusion
Broth (Difco, BHIB) to allow recovery of fastidious or low-
concentration organisms. Isolates were identified by standard
methods [15]. In some instances, unusual strains were
identified using partial 16S rRNA gene sequencing [16].
Antimicrobial susceptibility testing of the aerobic isolates
was performed using the standard disc diffusion method, as
recommended by the Clinical and Laboratory Standards
Institute [17]. Quantitative results were expressed in CFU/
mL for needle aspiration samples, CFU/g for biopsy samples
and CFU/cm2 for swab samples. Consistent with the study by
Bill et al. [18] and the results of a recent systematic review [19],
a swab count of >105 CFU/cm2 was considered equivalent to a
tissue count of >105 CFU/g or a needle aspiration sample of
>105 CFU/mL; all of these values are considered to represent a
clinically relevant tissue burden (CRTB).
2.7. Multidrug resistance profiles
Methicillin-resistant S. aureus (MRSA), methicillin-resistant S.
epidermidis (MRSE) and other coagulase-negative Staphylococcus
spp. (MRCN) were defined as strains phenotypically resistant
to cefoxitin (by the disc diffusion method). Vancomycin-
resistant Enterococcus spp. (VRE) were defined as strains thatwere phenotypically resistant to vancomycin. (ESBL)-produc-
ing gram-negative strains were phenotypically confirmed
using the cephalosporin/clavulanate combination disc test
[20]. Multi-drug resistant (MDR) P. aeruginosa and Acinetobacter
baumannii strains were defined as those resistant to at least
three of six antibiotics, including amikacin, gentamicin,
ciprofloxacin, piperacillin, ceftazidime and imipenem. Pan-
drug resistant (PDR) P. aeruginosa and A. baumannii/calcoaceticus
strains were defined as those sensitive only to colistin [21]. All
of these strains (MRSA, MRCN, VRE, [ESBL]-producing gram-
negative bacteria, and MDR and PDR P. aeruginosa and A.
baumannii/calcoaceticus) were considered to be MDR organisms.
2.8. Statistical analyses
Qualitative variables were expressed as percentages, and
quantitative variables are expressed as means  SD (standard
deviation). Significance of the study variables was tested using
Student’s t-test, the Chi-square test or Fisher’s exact test,
where appropriate. A two-tailed p value of <0.05 was
considered to be statistically significant. Additionally, the
ulcer duration (in days) was stratified by microbial isolate and
visually summarized in a box plot, with the boxes representing
the lower and upper quartiles, the vertical line the median, the
bars the minimum and maximum data points, and the solid
diamond symbol the mean.
3. Results
A total of 49 patients (mean age of 62.7  12.7 years and a male-
to-female ratio of 6.8) were admitted during the study period.
Their clinical and diabetic foot characteristics, stratified in
accordance with the sample collection method, are shown in
Table 1. Among these patients, the mean duration of DM was
23.0  12.8 years, 26.5% had HbA1c levels <58 mmol/mol
(<7.5%), >90% had hypertension and/or dyslipidemia, and
30.6% and 10.2% had ischemic heart disease and chronic renal
failure, respectively. Two-thirds of the patients had under-
gone recent antibiotic therapy, and one-third was currently
undergoing antibiotic therapy. The majority of the samples
came from outpatients (65.3%), and swabbing was the most
commonly used method (63.3%) for sample collection.
However, 92.8% of hospitalized patients and all clinically
suspected osteomyelitis patients had samples collected by an
invasive technique. There were statistically significant differ-
ences in the isolation rates of microorganisms from deep
tissue samples and superficial swabs, with fewer aerobes per
sample, in particular gram-positive bacteria (2.3  1.0 vs.
1.3  1.2), isolated from swabs, but there was no difference in
the isolation rate of anaerobes or MDR organisms.
Out of the 49 patients enrolled in this study, 147 microbial
isolates (comprising 43 species) were cultured, which repre-
sents an average of 3.0  1.4 organisms per sample. System-
atic results are presented in Table 2. Aerobes were present in
98.0% of cases, with gram-positive bacteria comprising 66.0%
of the total number of isolates. Staphylococcus was the main
genus identified, with S. aureus present in 51% of the samples
and in 94.1% of the cases with a CRTB. Coagulase-negative
Staphylococcus spp. were the second most frequently encoun-
Table 1 – Clinical and microbiological characteristics of DFIs stratified by the sample collection method.
Total (n = 49) Swab samples (n = 31) Deep tissue samplesa (n = 18)
Hospitalization (%) 34.7 12.9 72.2
Demographical data
Age (years) 62.7  12.7 60.2  13.5 67.0  10.1
Male gender (%) 83.7 87.1 77.8
Diabetes mellitus
Control of diabetes (HbA1c < 7%) 20.4% 16.1% 17.8%
Duration (years) 23.0  12.8 22.5  12.8 23.7  13.1
Co-morbidities
Hypertension (%) 93.9 96.8 88.9
Dyslipidemia (%) 95.9 93.4 100
Active tobacco abuse (%) 38.7 32.2 50.0
Organ lesions
Ischemic heart disease (%) 30.6 35.5 22.2
Chronic renal failure (%) 10.2 12.9 5.6
Diabetic foot characterization
Number of previous ulcers 1.6  1.5 1.9  1.6 1.2  1.2
Previous amputation (%) 46.9 51.6 38.9
Major 10.2 9.7 11.1
Minor 38.8 45.2 27.8
Duration of present ulcer (days) 30.6  31.9 33.4  25.9 25.7  40.5
Neuroischemic (%) 53.1 54.8 50.0
Osteomyelitis (%) 30.6 0.0 83.3
PEDIS
Perfusion
1 (%) 44.9 43.9 46.6
2 (%) 40.8 40.7 41.0
3 (%) 14.3 19.3 12.4
Extent (cm2) 13.3  56.9 1.2  0.6 34.3  91.7
Depth
1 (%) 18.4 29.0 0.1
2 (%) 51.0 71.0 16.6
3 (%) 30.6 0.0 83.3
Infection
2 (%) 61.2 87.1 16.6
3 (%) 36.7 12.9 77.7
4 (%) 2.0 0.0 5.4
Sensation
2 (%) 100 100 100
Antibiotic therapy
Previous (%) 65.3 67.7 61.2
Current (%) 30.6 23.0 43.7
Isolates
Monomicrobial (%) 16.3 12.9 22.1
Total number (per sample) 3.0  1.4 3.2  1.3 2.7  1.4
Aerobes 2.5  1.1 2.7  0.9 2.3  1.3
Gram-positive 2.0  1.0 2.3  1.0 1.6  1.1
Gram-negative 0.6  0.6 0.5  0.5 0.7  0.7
Anaerobes 0.4  0.6 0.4  0.6 0.3  0.6
MDR organisms 0.6  0.9 0.5  0.8 0.9  1.0
a Biopsies (n = 14) and aspirates (n = 4).
MDR: multi-drug resistant.
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Staphylococcus lugdunensis commonly associated with a CRTB.
Corynebacterium spp. and other uncommon gram-positive
bacteria were also identified but not in clinically significant
quantities. Streptococcus spp. were infrequently (4.1%) isolated.
Gram-negative aerobes comprised 19.0% of the isolated
organisms, while P. aeruginosa, the single most predominant
species, was isolated in only 12.2% of cases. Proteus spp. were
the next most frequently recovered gram-negative bacteria,
although largely (75.0%) in non-CRTB cases. A. baumannii/
calcoaceticus were identified in 8.2% of the cases and were thenon-PDR species found exclusively in the non-CRTB cases.
Anaerobes were found in 30.6% of patients, with Peptostrepto-
coccus spp. accounting for 55.0% of all anaerobic isolates,
followed by the Bacteroides fragilis group, which accounted for
25% of these isolates, but this last group was more frequently
identified in non-CRTB. Candida spp. were infrequently
encountered, representing only 1.4% of the total isolates.
MDR organisms were present in 38.8% of cases, while MRSA
was found in 24.5% of patients, thereby making it the
predominantly isolated pathogen. MRSE and other methicil-
lin-resistant coagulase-negative Staphylococci were also iden-
Table 2 – Distribution of the DFI isolates.
n % % (/patients) CRTB
Aerobes 125 85.0 98.0 63.2%
Gram-positive 97 66.0 95.9 64.9%
Staphylococcus spp. 54 36.7 79.6 66.7%
Staphylococcus aureus (MRSA) 32 (17) 21.8 (11.6%) 51.0 (24.5%) 93.8% (94.1%)
Staphylococcus epidermidis (MRSE) 7(3) 4.8 (2.0%) 14.3 (4.1%) 42.9% (66.7%)
Other coagulase-negative Staphylococcus spp. (MRCN)a 15 (3) 10.2 (2.0%) 20.4 (4.1%) 20.0% (33.3%)
Streptococcus spp.b 6 4.1 12.2 100%
Enterococcus spp.c (VRE) 13 (1) 8.8 (0.7%) 20.4 (2.0%) 76.9% (100%)
Corynebacterium spp.d 12 8.2 28.6 50.0%
Other Gram-positivese 12 8.2 22.4 41.7%
Gram-negative 28 19.0 51.0 57.1%
Enterobacteriaceae 16 10.9 16.3 56.3%
Escherichia coli 1 0.7 2.0 100%
Klebsiella spp. (ESBL) 2 (1) 1.4 (0.7%) 4.1 (2.0%) 100% (100%)
Proteus spp.f 8 5.4 16.3 25.0%
Other Enterobacteriaceaeg 5 3.4 4.1 80.0%
Nonfermenting negative bacilli 12 8.2 20.4 58.3%
MDR Pseudomonas aeruginosa (PDR-PA) 7(2) 4.8 (1.4%) 12.2 (4.1%) 71.4% (100%)
MDR Acinetobacter baumannii/calcoaceticus (PDR-AB) 5 (3) 3.4 (2.0%) 8.2 (6.1%) 40.0% (66.7%)
Anaerobes 20 13.6 30.6 75.0%
Peptostreptococcus spp. 11 7.5 22.4 100%
Bacteroides fragilis group 5 3.4 4.1 20.0%
Other anaerobesh 4 2.7 4.1 75.0%
Yeastsi 2 1.4 4.1 –
In brackets are the multi-drug resistant (MDR) organisms of each species; CRTB: clinically relevant tissue burden; MRSA: methicillin-resistant
Staphylococcus aureus; MRSE: methicillin-resistant Staphylococcus epidermidis; MRCN: methicillin-resistant coagulase-negative Staphylococcus spp.
other than Staphylococcus epidermidis; VRE: vancomycin-resistant Enterococci; ESBL: extended-spectrum beta-lactamases producing Enterobacter-
iaceae; MDR: multi-drug resistant; PDR-PA/PDR-AB: pan-drug-resistant Acinetobacter baumannii/pandrug-resistant Pseudomonas aeruginosa.
a Staphylococcus lugdunensis (n = 2) and other coagulase-negative Staphylococcus spp. (n = 13).
b Streptococcus agalactiae (n = 3), Streptococcus mitis group (n = 1) and Streptococcus dysgalactiae (n = 2).
c Enterococcus faecalis (n = 9) and Enterococcus faecium (n = 1).
d Corynebacterium amycolatum/striatum (n = 9) and other Corynebacterium spp. (n = 3).
e Dermabacter hominis (n = 1), Leuconostoc spp. (n = 1), Arcanobacterium spp. (n = 2), Arthrobacter spp. (n = 1), Kocuria varians/rosea (n = 2),
Cellulomonas spp./Micrococcus spp. (n = 1) and Brevibacterium spp. (n = 4).
f Proteus mirabilis (n = 4) and Proteus vulgaris (n = 4).
g Enterobacter spp. (n = 1), Serratia marcescens (n = 2) and Morganella morganii (n = 2).
h Fusobacterium spp. (n = 1), Prevotella spp. (n = 1), Eggerthella spp. (n = 1) and Veinonella spp. (n = 1).
i Candida albicans (n = 1) and Candida parapsilosis (n = 1).
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negative MDR organisms were identified in a total of 18.9% of
the patients. Of the isolated A. baumannii and P. aeruginosa
strains, 38.5% were PDR, and the remainder were MDR.
Although a longitudinal study using sequential microbio-
logical samples was not performed, visually representing the
relationship between the microbial isolates and ulcer duration
in a box plot graph (Fig. 1) revealed a pattern: gram-positive
bacteria appeared in ulcers of short duration, while anaerobes
associated with either gram-positive or -negative organisms
appeared in ulcers of longer duration. This finding was
independent of previous or current antimicrobial therapy.
The average duration of an ulcer with any isolated MDR
organism was 29 days.
In the clinical samples collected from patients undergoing
antibiotic therapy (Table 3), which corresponded mainly to
hospitalized patients with osteomyelitis, 93% of the antibiotic
regimens were considered inadequate based on the antibiotic
susceptibility test results. Quantitative and qualitative differ-
ences were found in these samples, with fewer microorgan-
isms identified (2.1  0.9 vs. 3.4  1.3); in particular, fewer
gram-positive (86.7% vs. 100%) and anaerobic (6.7% vs. 41.2%)bacteria were identified; however, there was a higher preva-
lence of MDR organisms (66.7% vs. 26.5%). Although all the
clinical variables were examined, multi-drug resistance was
only statistically associated with current antibiotic treatment
(with any class of antibiotics) and with previous fluoroquino-
lone treatment (Table 4).
4. Discussion
DFIs are common, complex, and costly. They account for the
largest number of proximate nontraumatic lower extremity
amputations [2]. This public health problem is particularly
important in the underdiagnosed and undertreated diabetic
Portuguese population [8]. To our knowledge, this is the first
published epidemiological study that reports the infectious
microbiota and clinical characteristics of diabetic foot in
patients located in Portugal. This study reflects the clinical
profiles of inpatients and outpatients in the Lisbon area, but
because the sample was relatively small, the study population
was heterogeneous, and some controversial methodological
issues were utilized (notably, the use of swabs and quantita-
Fig. 1 – A box plot representing the ulcer duration data (in days), stratified by the microbial isolate (the boxes represent the
lower and upper quartiles, the vertical line the median, the bars the minimum and maximum data points, and the solid
diamond symbol the mean). MDROs: multi-drug resistant organisms, GP: gram-positive aerobes, GN: gram-negative
aerobes, and A: anaerobes.
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results.
The baseline characteristics of the sample population are
in line with those previously reported by European DFU
studies [22], except for the high percentage of male patients
and low percentage of patients with controlled DM (as
evaluated by HbA1c). This can be partially explained by the
hypothesis of a recent study [23] that reported that male
gender and poor glycemic control are independent risk factors
for infection and non-healing DFUs. The high prevalence of co-
morbidities is due to the low cut-offs used in the definitions.Table 3 – Distribution of the DFI isolates in relation to current
Total
(n = 49)
Hospitalization (%) 34.7 
Isolates
Total number (per sample) 3.0  1.4 
Aerobes
Number present per sample 2.5  1.1 
Samples with 1 (%) 98.0 
Gram-positive
Number present per sample 2.0  1.0 
Samples with 1 (%) 95.9 
Gram-negative
Number present per sample 0.6  0.6 
Samples with 1 (%) 51.0 
Anaerobes
Number present per sample 0.4  0.6 
Samples with 1 (%) 30.6 
MDR organisms
Number present per sample 0.6  0.9 
Samples with 1 (%) 38.8 
Antibiotic therapy covers isolated pathogens – 
a Not under antibiotic therapy vs. under antibiotic therapy.
b Of the total of patients current undergoing antibiotic therapy.Clinical guidelines [6] use infection severity and other
clinical characteristics of DFUs as the basis for selecting an
appropriate treatment approach, including antibiotic therapy.
Our study used the PEDIS classification, and there were no
statistical relationships between the diabetic foot character-
istics, other than the duration of the ulcer and a clinical
suspicion of osteomyelitis, and specific pathogens. We cannot
be certain that the lack of significant associations was due only
to the small sample size, however.
It is well documented in the literature [3,4] that DFIs are
polymicrobial in nature. In the present study, polymicrobial antibiotic therapy.
Not under antibiotic
therapy (n = 34)
Under antibiotic
therapy (n = 15)
pa
17.6 73.3 <0.01
3.4  1.3 2.1  0.9 <0.01
2.9  1.0 1.9  1.0 <0.01
100 93.3 NS
2.3  1.0 1.5  1.1 0.02
100 86.7 0.03
0.6  0.6 0.4  0.6 NS
58.8 33.3 NS
0.5  0.6 0.1  0.5 NS
41.2 6.7 0.01
0.4  0.7 1.1  1.0 <0.01
26.5 66.7 <0.01
– 7.0%b –
Table 4 – Relationship between MDR organisms and recent (=3 months) or current antibiotic therapy.
Non-MDR (n = 30) MDRa (n = 19) pb
Previous antibiotic therapy 63.3% 73.7% NS
Penicillins (including associations with b-lactamase inhibitors) 63.3% 79.0% NS
Cephalosporins 13.3% 26.3% NS
Carbapenems 10.0% 5.3% NS
Aminoglycosides 0.0% 0.0% NS
Sulphamides 13.3% 15.8% NS
Fluoroquinolones 23.3% 63.2% <0.01
Glycopeptides 6.7% 5.3% NS
Oxazolidinones 0.0% 5.3% NS
Others 3.3% 5.3% NS
Current antibiotic therapy 16.7% 52.6% <0.01
Penicillins (including associations with b-lactamase inhibitors) 6.7% 0.0% NS
Cephalosporins 0.0% 0.0% NS
Carbapenems 10.0% 15.8% NS
Aminoglycosides 0.0% 5.3% NS
Sulphamides 3.3% 0.0% NS
Fluoroquinolones 10.0% 15.8% NS
Glycopeptides 3.3% 5.3% NS
Oxazolidinones 0.0% 5.3% NS
Others 0.0% 5.3% NS
Covers the isolated pathogens 40.0% 0.0% 0.03
a MRSA, MRSE, MRCN, VRE, ESBL-producing negatives, PDR Pseudomonas aeruginosa and PDR Acinetobacter baumannii/calcoaceticus.
b Non-MDR vs. MDR.
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isolation of 3.0  1.4 bacteria per patient, independent of the
sampling method, which is similar to the results seen in
previous studies. In agreement with published western
studies [3,4], we isolated predominantly aerobic gram-positive
cocci from acute infections, while a more complex flora,
including gram-negative and anaerobic bacteria was obtained
from chronic wounds.
We also found that S. aureus, either alone or as a component
of a mixed infection, to be the most frequently isolated
pathogen. Coagulase-negative Staphylococcus spp. were also
frequently found, often with a methicillin-resistance pheno-
type. Streptococcus spp., which are well-recognized pathogens
in DFIs, were infrequently isolated. This can be partially
justified by the high prevalence of present and recent
antibiotic therapy. Enterococcus spp., considered low-virulence
commensal organisms, except in diabetic and other compro-
mised patients, were identified in 20.4% of patients, which is in
accordance with other studies [3,4].
In strict accordance with other western studies [3,4], but
unlike studies from India and other Asian countries [24], we
isolated relatively few aerobic gram-negative organisms.
In our study, the high percentage of P. aeruginosa and low
percentage of Proteus spp. isolates with a CRTB was consistent
with the view that the first species can cause severe tissue
damage in DM patients and should be regarded as significant
in that population, while the latter are most commonly non-
pathogenic [7].
Independent of the sampling method, anaerobes were
isolated in one-third of the patients and almost always in
mixed culture. This is in contrast to the findings of several
other studies that failed to isolate anaerobes, possibly because
of suboptimal study protocols [25]. The anaerobes isolated
from our study are consistent with other reported studies [26],
in which Peptostreptococcus spp. were the predominant isolates.Although the exact role of anaerobic bacteria in DFIs is still
under debate, our study is in line with the expert opinion [7]
that suggests that anaerobes are more likely to be isolated
from long-standing infections.
Other important factors to consider when interpreting the
results of our study are that DFI is a clinical diagnosis and that
both the quantitative and qualitative aspects of wound
microbiology are critical determinants of an infection’s
course. All the patients enrolled in our study had clinically
infected DFUs, and we based our conclusions on a qualitative
microbiological analysis, considering the diversity of the
microorganisms and the potential for microbial synergy,
and on quantitative microbiological analysis, which provided
a good indication of the microbial load. Assuming that the
qualitative microbiology remains constant, the probability of
wound infection increases with the microbial load, up to a
critical level at which infection or a failure to heal is
considered to be almost inevitable. In this paper, CRTB
represented the quantitative aspect of wound microbiology
and was used only as a potential indicator of the microorgan-
isms’ relevance in clinically infected DFUs.
One of the main limitations of our study is that the
quantitative and qualitative microbial evaluations were
predominantly performed using swab samples. While tissue
biopsies and fluid aspirates are considered the gold standard
for diagnosing wound infections [25], these invasive tests are
performed infrequently with small wounds and in many
practice settings, such as outpatient clinics, due to concerns
over enlarging the ulcer or inducing pain [14,25,27]. In our
study, we introduced a standardized procedure that was
strictly consistent with the current clinical guidelines [6]. Our
method used quantitative aerobic and anaerobic swab
cultures as an alternative method when the HCP believed
an invasive procedure would place the patient at risk. While
this decision was based on the microbiological experimental
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results form quantitative swabs are highly correlated with
those from invasive procedures (sensitivities from 93.5% to
100% and specificities from 76.3% to 94.2% have been
previously reported [14]), this hypothesis is not consensual
in the scientific community. Some authors have reported
consistency between swab and deep tissue biopsy sample
cultures [28,29], while others believe that superficial swab
cultures of DFIs only complicate patient evaluation by
sampling the superficial wound compartment, which may
contain colonizing organisms rather than true pathogens.
These divergent conclusions may be explained by different
and non-standardized protocols. While we acknowledge that a
standardized quantitative swab sampling protocol may be an
imperfect and difficult-to-implement method in the clinical
setting, it clearly has merits in the research field, at least in a
setting with a high prevalence of the multi-drug resistance
setting such as in our study; when properly interpreted, they
can provide useful information [27].
We had a surprisingly high number of swab samples
(mainly from outpatient clinics) from patients with small
superficial ulcers. There were statistically significant differ-
ences between the superficial and deep samples, probably due
to swab-associated and impossible-to-eliminate wound con-
tamination by members of the endogenous microbiota
(mainly gram-positive aerobes). This result may explain the
high prevalence of Corynebacterium spp. and other low-
virulence colonizers (e.g., Dermabacter hominis and Leuconostoc
spp.), which were mainly cultured from swab samples.
In the present study, MDR organisms were cultured from
38.8% of the patients, the majority (24.5%) of which were
MRSA. Most of the other international studies that have
reported a similarly high percentage of MDR organisms were
single-center, hospital-based studies [24]. The high prevalence
in such studies may be explained by the institution’s use of
broad spectrum antibiotics, resulting in a pathogen-selective
survival advantage. In our multicenter study, we did not find
any statistically significant differences between the inpatients
and outpatients, and the mean duration of ulcers with isolated
MDR organisms was short (29 days).
We also found a high percentage of patients (65.3%) who
had received antibiotics in the previous three months and a
statistical association between the presence of MDR organ-
isms and previous fluoroquinolone therapy. This class of
antibiotics has been widely used in Portugal for many years
[30], and others have described [31] how they use correlates
with the spread of MDR organisms, particularly MRSA.
Therefore, our results suggest that multi-resistance in our
area is widespread in diabetic patients with foot ulcers, and
fluoroquinolone abuse (including inadequate dosing or sub-
optimal therapy duration) in the community could be a
potential cause.
We also evaluated samples from DFI patients receiving
antibiotic therapy, mainly hospitalized patients with osteo-
myelitis, who had signs of infection progression and clinical
deterioration of their ulcers. Microbial isolation was signifi-
cantly influenced by systemic antibiotic therapy, with fewer
microorganisms (mostly anaerobic bacteria) identified but
with a significantly greater prevalence of MDR organisms. This
finding may be explained by selective pressure because themajority of these patients were under broad-spectrum
antibiotic therapy, mostly with carbapenems. There are
surprisingly few published clinical trials on antibiotic therapy
for DFIs, and the available data do not allow current guidelines
to recommend any specific antibiotic regimen. In 2010,
however, the Portuguese Directorate-General of Health [32]
published a clinical guideline suggesting the use of isoxazo-
lylpenicillins or clindamycin for superficial infections, ami-
nopenicillins with a b-lactamase inhibitor or fluoroquinolones
combined with clindamycin for deep infections, and carba-
penems or ureidopenicillins with a b-lactamase inhibitor for
more severe infections. The same guideline also considered
the potential use of cotrimoxazole, vancomycin, linezolid or
tigecycline if MRSA was suspected but did not mention any
suspicion criteria. Although these guidelines are typically
considered by HCPs, our study showed that the initial
empirical antibiotic therapy covered the isolated pathogens
of patients with clinically deteriorating ulcers in only 7.0% of
the cases. Therapeutic failure was related to the presence of
MDR organisms, namely MRSA.
In conclusion, our observational study provides a unique
picture of the DFI pattern in our region. Both the prevalence
and precocity of MDR organisms were alarmingly high and
were probably related to indiscriminate antibiotic use.
Fluoroquinolones, because of their pharmacological charac-
teristics, safety and proven clinical effectiveness, are among
the antimicrobial agents currently recommended by authori-
tative DFI guidelines. However, resistance has been directly
linked to the use of these compounds, and the present study
describes a statistical association that should encourage
clinicians, and ultimately health authorities, to avoid their
widespread use. By contrast, due to the high prevalence of
MRSA in DFIs in our area, we suggest empirical anti-MRSA
therapy followed by de-escalation to rationalize care and
improve outcomes.
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